Schizophrenia trials in Italy
12 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleEvenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics
- Where
- Brescia, Milan, Naples, Rome
- Age
- 18 years and over
- People
- 135 worldwide
- Run by
- Newron Pharmaceuticals S.p.A.
See details and how to join2024-519836-18-00 · EU 2024-519836-18-00 - Phase 2Taking peopleA Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
- Where
- Arzignano, Brescia, Cefalù, Tricase
- Age
- 55 years and over
- People
- 370 worldwide
- Run by
- Intra-Cellular Therapies, Inc.
See details and how to joinNCT06540833 - Phase 3Taking peopleA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Where
- Brescia, Milan, Rome
- Age
- 55 years to 90 years
- People
- 406 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00 - Phase 3Taking peopleStratification and Treatment in Early Psychosis Study - ENHANCE
- Where
- Naples
- Age
- 16 years to 40 years
- People
- 250 worldwide
- Run by
- University of Oxford
See details and how to joinNCT06778564 · EU 2025-521929-32-00 - Phase 3Not yet taking people in ItalyStratification and Treatment in Early Psychosis Study -ASSIST
- Where
- Naples
- Age
- 16 years to 50 years
- People
- 250 worldwide
- Run by
- University of Oxford
See details and how to joinNCT07326124 - Phase 3Not yet taking people in ItalyStratification and Treatment in Early Psychosis Study - PROMOTE
- Where
- Bari, Naples, Pavia, Roma
- Age
- 12 years to 35 years
- People
- 586 worldwide
- Run by
- University of Oxford
See details and how to joinNCT07434973 - Phase 2Taking peopleA Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Where
- Rome, Tricase
- Age
- 55 years to 90 years
- People
- 300 worldwide
- Run by
- MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00 - Phase 2Enrolling by invitationAn Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
- Where
- Rome, Tricase
- Age
- 55 years to 91 years
- People
- 210 worldwide
- Run by
- MapLight Therapeutics
See details and how to joinNCT07459660 · EU 2025-521757-16-00 - No phaseNot yet taking people in ItalyNon-Coding RNAs Gene Expression in Psychiatric Disorders
- Where
- Catania, Enna, Messina, Palermo
- Age
- 18 years to 55 years
- People
- 384
- Run by
- Carmen Concerto
See details and how to joinNCT07649993 - Phase 4Taking peopleThe Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
- Where
- Brescia, Cagliari, Naples, Turin
- Age
- 18 years to 70 years
- People
- 418 worldwide
- Run by
- Dr. Inge Winter
See details and how to joinNCT05958875 · EU 2023-506602-39-00 - No phaseTaking peopleAn Integrated Neurophysiological Approach Toward the Early Detection of Psychiatric Disorders
- Where
- Brescia
- Age
- 18 years to 50 years
- People
- 75
- Run by
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
See details and how to joinNCT06886945 - Phase 1Not yet taking people in ItalyA Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia
- Where
- Bourgas
- Age
- 18 years and over
- People
- 170 worldwide
- Run by
- Geneora Pharma (Shijiazhuang) Co. Ltd.
See details and how to join2023-508981-13-00 · EU 2023-508981-13-00